Stryker Co. (NYSE:SYK) Stock Holdings Boosted by Tilia Fiduciary Partners Inc.

Tilia Fiduciary Partners Inc. lifted its position in shares of Stryker Co. (NYSE:SYK) by 1.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 7,188 shares of the medical technology company’s stock after acquiring an additional 113 shares during the period. Stryker accounts for 1.8% of Tilia Fiduciary Partners Inc.’s portfolio, making the stock its 14th biggest holding. Tilia Fiduciary Partners Inc.’s holdings in Stryker were worth $2,676,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SYK. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker in the fourth quarter worth about $25,000. Capital A Wealth Management LLC acquired a new stake in Stryker in the fourth quarter worth about $26,000. Rakuten Securities Inc. lifted its holdings in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new stake in Stryker in the fourth quarter worth about $30,000. Finally, BankPlus Trust Department acquired a new stake in Stryker in the fourth quarter worth about $33,000. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of SYK stock opened at $384.15 on Friday. The stock has a 50-day moving average price of $370.10 and a 200 day moving average price of $375.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The firm has a market cap of $146.63 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 2.93 and a beta of 0.91. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the company earned $2.50 earnings per share. Research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 45.41%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Truist Financial upped their price target on shares of Stryker from $390.00 to $400.00 and gave the company a “hold” rating in a report on Monday, May 5th. BTIG Research set a $403.00 target price on Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Friday. Citigroup reissued a “buy” rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Evercore ISI reduced their target price on Stryker from $400.00 to $390.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.